Competition

Corporate / M&A

Employment and Executive Compensation

Healthcare / Life Sciences

IP / IT

Real Estate

Regulatory

Homburger for Biotronik

Homburger News

20250311_Biotronik

Homburger advises BIOTRONIK on sale of VI Business to Teleflex

On February 27, 2025, BIOTRONIK Group announced that it has entered into an agreement to divest its Vascular Intervention (VI) business division to Teleflex Incorporated. The transaction is subject to regulatory approvals and other customary closing conditions and is expected to close before the end of the third quarter of 2025.
BIOTRONIK is a Berlin-based global leader in medical technology and a pioneer in cardiovascular, endovascular, and neuromodulation solutions. Teleflex (NYSE: TFX) is a Pennsylvania-based leading global provider of medical technologies with a diverse portfolio, including solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.
Homburger acts as Swiss transaction counsel to BIOTRONIK. The team includes Andreas Müller, Anna Peter, Jasmin Künzle, Romain Hondius, Oliver Kneubühl and Cédric Berger (all Corporate / M&amp;A), Richard Stäuber and Angelika Murer (both Regulatory), Luca Dal Molin and Philippe Baumann (both IP / IT), Stefan Gäumann (Real Estate), Jeremy Reichlin and Angela Casey (both Employment and Executive Compensation), as well as Reto Heuberger and Philippe Weber (both Tax).

Financing and Investment Products

Data Protection

Arbitration

HomeToGo_web_640x140

On February 12, 2025, HomeToGo SE (Frankfurt Stock Exchange: HTG) announced the signing of a binding agreement to acquire Interhome, Europe&#8217;s second largest vacation rental management company, from Migros, Switzerland’s largest retail company. HomeToGo agreed to a purchase price of CHF 150 m, plus deferred payments of up to CHF 85 m which may become due in tranches until 2029, making this the most significant transaction in HomeToGo Group&#8217;s history and positioning HomeToGo to become Europe&#8217;s leading vacation rental platform.
With this transaction, HomeToGo Group&#8217;s total pro-forma Adjusted EBITDA for FY/24e would triple to more than EUR 30 m.
The transaction is expected to be financed through a combination of new equity, senior debt and available net cash and is expected to close in H1/25, subject to customary regulatory approvals for both the acquisition of Interhome by HomeToGo and the simultaneous acquisition &#8211; in the same transaction &#8211; of the other entities in Hotelplan Group by DERTOUR Group, a renowned international tourism group.
Homburger advises HomeToGo on the Swiss law and tax aspects of the transaction. The Homburger team was led by Frank Gerhard (Corporate / M&amp;A) and included Olivier Bühlmann, Magdalena Stock, Daniel Bötticher, Miriam Oelgarth and Harun Cetin (all Corporate / M&amp;A), Stefan Bindschedler and Michelle Wolf (both Financing and Investment Products), Luca Dal Molin and Joel Fink (both IP / IT), Richard Stäuber and Christoph Grüninger (both Competition), Reto Heuberger, Stefan Oesterhelt and Philippe Weber (all Tax), Vanessa Huber and Jeremy Reichlin (both Employment and Executive Compensation), Gabriel Kasper (Data Protection) as well as Stefanie Pfisterer (Arbitration). Homburger acted alongside a German-based Linklaters team on this transaction.

Homburger advises HomeToGo on its acquisition of Interhome

Capital Markets

Bioversys

20250129_Bioversys

On January 29, 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, announced the launch of its Initial Public Offering (IPO) on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. The IPO comprises a primary offering targeting gross proceeds of CHF 80 m (including an over-allotment option targeting gross proceeds of CHF 5 m). The implied market capitalization of the company, assuming all offered shares are sold in the IPO and the over-allotment option is exercised in full, is approximately CHF 212.9 m. The first day of trading is expected to be February 7, 2025.
BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The Company&#8217;s most advanced R&amp;D programs address nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a). In addition to its domicile in the biotech hub in Basel, Switzerland, BioVersys has operations in in Lille, France, Delaware, United States and Guangzhou, China.
Citigroup Global Markets Limited, UBS AG and Stifel Europe AG are acting as Joint Global Coordinators and Joint Bookrunners on the IPO, Mirabaud &amp; Cie SA and Octavian AG as Selling Agents.
Homburger is advising BioVersys on all aspects of the IPO as lead counsel. The Homburger team is co-led by Dieter Gericke and Lorenzo Togni and includes Thierry Burckhardt, Magda Aref, Simone Schmid, Raphael Linder, Harun Cetin and Leander Etter (all Corporate / M&amp;A and Capital Markets). Luca Dal Molin and Kristina Martinovic (both IP / IT) are providing intellectual property advice, Jeremy Reichlin (Employment and Executive Compensation) is providing employment and executive compensation advice, and Reto Heuberger and Philippe Weber (both Tax) are providing tax advice.

Philippe
Weber

Homburger advises BIOTRONIK on sale of VI Business to Teleflex

Homburger advises HomeToGo on its acquisition of Interhome

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Join the Team

Philippe Weber

Career

Languages

Bar Registration

Teams

PhilippeWeber

Homburger advises BIOTRONIK on sale of VI Business to Teleflex

Homburger advises HomeToGo on its acquisition of Interhome

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Join the Team

Philippe Weber

Career

Languages

Bar Registration

Teams

Philippe
Weber